The Carlos III Health Institute (ISCIII) has published the final resolution of grant awards corresponding to the 2025 Strategic Action in Health (AES 2025), the main funding instrument for biomedical and health research in Spain.

Within these calls, the Accredited Vall d’Hebron Institute has secured funding for a total of 43 projects, with an overall amount of €8,053,450.95. This result highlights the institute’s strong competitiveness and the high scientific level of the research carried out on the campus.

The projects awarded under the Health R&D&I Projects call address a wide range of areas and pathologies, reflecting diverse research that is closely aligned with today’s major biomedical and healthcare challenges. These initiatives span multiple fields of health and contribute to advancing knowledge, diagnosis, and treatment of numerous diseases.

In addition, the Accredited Vall d’Hebron Institute has obtained funding through the Health Technology Development and Independent Clinical Research calls, further strengthening its commitment to innovation, knowledge transfer, and patient-oriented clinical research.

The results achieved in AES 2025 confirm Vall d’Hebron’s robustness as an ISCIII-accredited research institute and demonstrate the quality of the submitted projects, as well as the sustained efforts of its research teams to promote excellence in research with a real impact on public health.

Below is the list of the groups and researchers leading the awarded projects:

Health R&D&I Projects

• Luis Gerardo Alcalá and Alfredo Guillén, from the Physiology and Pathophysiology of the Digestive Tract Group (VHIR)
• Gema Ariceta, from the Kidney Physiopathology Group (VHIR)
• Gara Arteaga, from the Psychiatry, Mental Health and Addictions Group (VHIR)
• Cristina Berastegui, from the Pneumology Group (VHIR)
• Mª Jesús Cruz, from the Pneumology Group (VHIR)
• María Pilar Delgado, from the Cardiovascular Diseases Group (VHIR)
• Mª Alba Erra and Xabier Michelena, from the Rheumatology Group (VHIR)
• Christian Fadeuilhe and José Antonio Ramos-Quiroga, from the Psychiatry, Mental Health and Addictions Group (VHIR)
• Ignacio Ferreira and Laura Galian, from the Cardiovascular Diseases Group (VHIR)
• Concepción Gómez, from the Hepato-bilio-pancreatic (HBP) Surgery and Liver Transplantation Group (VHIR)
• Susana Gómez and Berta Sáez, from the Pneumology Group (VHIR)
• David Gómez and María Pallarés, from the Therapies and Innovations in Neuropediatrics and Other Pediatric Rare Diseases Group (VHIR)
• Cristina Hernández, from the Diabetes and Metabolism Group (VHIR)
• Nara Ikumi and Marta Torres, from the Headache and Neurological Pain Group (VHIR)
• Jiahui Li and Carlos Molina, from the Stroke Research Group (VHIR)
• Franco Marinello, from the General Surgery Group (VHIR)
• Mónica Martínez and Susana Melendo, from the Translational Immunology Group (VHIR)
• Manel Mendoza, from the Maternal and Fetal Medicine Group (VHIR)
• Joan Minguell and Nayana Joshi, from the Reconstructive Surgery of the Locomotor System Group (VHIR)
• Beatriz Mínguez, from the Liver Diseases Group (VHIR)
• Israel Molina and Pau Bosch, from the Infectious Diseases Group (VHIR)
• Mª Antonia Poca, from the Neurotraumatology and Neurosurgery Research Group (UNINN) (VHIR)
• Patricia Pozo and Víctor José Gallardo, from the Headache and Neurological Pain Group (VHIR)
• Marc Ribó, from the Stroke Research Group (VHIR)
• María del Mar Riveiro, from the Liver Diseases Group (VHIR)
• Anna Rosell, from the Neurovascular Diseases Group (VHIR)
• Mònica Sabaté, from the Clinical Pharmacology Group (VHIR)
• Fernando M. Salvador, from the Infectious Diseases Group (VHIR)
• Adrián Sánchez, from the Infectious Diseases Group (VHIR)
• Jaume Sastre, from the Clinical Neuroimmunology Group (VHIR)
• Maria Soler and Laura Gisbert, from the Psychiatry, Mental Health and Addictions Group (VHIR)
• Pere Soler and Natalia Ana Mendoza, from the Infection and Immunity in Pediatric Patients Group (VHIR)
• Ana Villar, from the Pneumology Group (VHIR)
• Josep A. Villena, from the Diabetes and Metabolism Group (VHIR)
• Marta Crespo, from the Experimental Hematology Group (VHIO)
• Andrés Jerez, from the Experimental Hematology Group (VHIO)
• Joaquim Mateo, from the Prostate Cancer Research Group (VHIO)
• Pedro Rocha, from the Thoracic Tumors Group (VHIO)
• Joan Seoane, from the Gene Expression and Cancer Group (VHIO)
• Cristina Suárez, from the Genitourinary (Non-Prostate), Central Nervous System (CNS) Tumours, Sarcomas and Tumours of Unknown Origin Group (VHIO)

Health Technology Development

• Marc Ribó, from the Stroke Research Group (VHIR)
• Alena Gros, from the Tumor Immunology and Immunotherapy Group (VHIO)

Independent Clinical Research

• David Rodríguez and Carlos Molina, from the Stroke Research Group (VHIR)